Genmab — Marts 2017
-
Mindre dara studie uden for kræft - https://clinicaltrials.gov/ct2/show/NCT03095118?term=pgnimd&rank=1
-
God morgen.
-
-
I den udstrækning Genmab kan styre nye kliniske forsøg tror jeg man kan være rolig. De har klart giver udtryk for at de ville have skrottet mange af de forsøg andre virksomheder har gang i. At de kun satser på ting som har en god sandsynlighed for st lykkes. I hvert fald når det gælder nye produktkandidater. Dara er naturligvis "godkendt" og en succes så om de der lader flere forsøg slippe igennem ved man naturligvis ikke.
-
HSBC hæver målkurs på Genmab til 812 fra 640. Beholder reducer anbefaling.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind